Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

INTRODUCTION: Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiltz, Uta, Sfikakis, Petros P., Gaffney, Karl, Sator, Paul-Gunther, von Kiedrowski, Ralph, Bounas, Andreas, Gullick, Nicola, Conrad, Curdin, Rigopoulos, Dimitris, Lespessailles, Eric, Romanelli, Marco, Ghislain, Pierre-Dominique, Brandt-Jürgens, Jan, Rashkov, Rasho, Aassi, Maher, Orsenigo, Roberto, Perella, Chiara, Pournara, Effie, Gathmann, Sven, Jagiello, Piotr, Veit, Justyna, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467439/
https://www.ncbi.nlm.nih.gov/pubmed/32378070
http://dx.doi.org/10.1007/s12325-020-01352-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467439/
https://www.ncbi.nlm.nih.gov/pubmed/32378070
http://dx.doi.org/10.1007/s12325-020-01352-8

Ejemplares similares